ArticleHormones (Athens, Greece)2022
Syzygium aromaticum bud (clove) essential oil is a novel and safe aldose reductase inhibitor: in silico, in vitro, and in vivo evidence.
Article in Hormones (Athens, Greece), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- GC-MS Profiling, Antioxidant and Enzyme Inhibitory Activities of Basil (Molecules (Basel, Switzerland) · 2026Article
- Optimized Extraction and Bioactivity Profiling of Phenolics from Bostrychia scorpioides (Hudson) Mont: A Sustainable Approach for Pharmaceuticals Applications.Marine biotechnology (New York, N.Y.) · 2026Article
- Syzygium aromaticum L. (Clove): A Comprehensive Reveiw of Its Ethnopharmacological Uses and Pharmacological Activities.Chinese journal of integrative medicine · 2026Review
- Article
- Bioactive assessment of hexahydroquinoline derivatives preparedRSC medicinal chemistry · 2025Article
- Plant-Based Diets and Phytochemicals in the Management of Diabetes Mellitus and Prevention of Its Complications: A Review.Nutrients · 2024Review
- Nanoemulsified Essential Oil ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Syzygium aromaticum essential oil and its major constituents: Assessment of activity against Candida spp. and toxicity.PloS one · 2024Article
- Antioxidant and Hypoglycemic Potential of Essential Oils in Diabetes Mellitus and Its Complications.International journal of molecular sciences · 2023Review
- Exploration of Clove Bud (Insects · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the antioxidant and antidiabetic properties of clove essential oil (CEO) and to elucidate its mode of action, using selected biochemical targets, relevant to diabetes, and, specifically, its inhibitory effect on the polyol pathway.
methodsIn the current study, CEO was examined for its inhibitory effects on aldose reductase in silico, in vitro, and in vivo, as well as its antioxidative activity.
resultsIn silico docking studies showed that all the selected major compounds of CEO have an energy change ranging between - 5.5 and - 8.8 kcal/mol and an inhibition constant ranging between 357.08 nM and 93.12 µM. CEO significantly inhibits aldose reductase with an IC
conclusionCEO potentially exerts a beneficial effect on diabetes-related complications due to its antioxidant and inhibitory effect on aldose reductase activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.